BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt

BriaCell Therapeutics Corp.

Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.
R&D expenses surged to $237,501 from $48,500, driven by wages $161,875 and supplies $75,626.
Cash remains $1; total assets $180,708; current liabilities $1,403,120 (including $1.31M due to parent BriaCell).
Shareholders' deficit $1,390,648; accumulated deficit $1,425,163; going concern uncertainty noted as dependent on BriaCell funding.
No auditor review performed; warrants liability $168,236 with Black-Scholes valuation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.